Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04134715 · ClinicalTrials.gov registry record · Phase 1
A Drug Drug Interaction Study Between PF-06826647 And Oral Contraceptive Steroids In Healthy Female Participants
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT04134715 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 15 participants.
The verdict
NCT04134715, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
This is a Phase 1, fixed sequence, multiple dose, open label study of the effect of PF-06826647 on oral contraceptive (OC) pharmacokinetics (PK) and vice versa in healthy female participants. A total of approximately 15 healthy female participants will be enrolled and dosed to achieve at least 12 participants completing the study.
Interventions
- DRUG PF-06826647
- DRUG Oral Contraceptive (OC)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2019-10-23 |
| Est. Completion | 2020-01-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04134715
The ClinicalTrials.gov registry entry for NCT04134715 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which PF-06826647 is the first listed.
NCT04134715 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04134715 about?
NCT04134715 is a clinical study titled "A Drug Drug Interaction Study Between PF-06826647 And Oral Contraceptive Steroids In Healthy Female Participants". This is a Phase 1, fixed sequence, multiple dose, open label study of the effect of PF-06826647 on oral contraceptive (OC) pharmacokinetics (PK) and vice versa in healthy female participants. A total of approximately 15 healthy female participants will be enrolled and dosed to achieve at least 12 pa...
What is the current status of trial NCT04134715?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2019-10-23. Estimated completion is 2020-01-09.
What interventions are being tested in trial NCT04134715?
The interventions under investigation include: PF-06826647 (DRUG), Oral Contraceptive (OC) (DRUG).
Who is sponsoring clinical trial NCT04134715?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.